



Identification of a Novel Link between the Protein Kinase NDR1 and TGF β Signaling in Epithelial Cells

Citation

Pot, Isabelle, Shachi Patel, Lili Deng, Amrita Singh Chandhoke, Chi Zhang, Azad Bonni, and Shirin Bonni. 2013. "Identification of a Novel Link between the Protein Kinase NDR1 and TGF β Signaling in Epithelial Cells." PLoS ONE 8 (6): e67178. doi:10.1371/journal.pone.0067178. <http://dx.doi.org/10.1371/journal.pone.0067178>.

Published Version

[doi:10.1371/journal.pone.0067178](https://doi.org/10.1371/journal.pone.0067178)

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717563>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Identification of a Novel Link between the Protein Kinase NDR1 and TGF β Signaling in Epithelial Cells

Isabelle Pot^{1,9}, Shachi Patel^{1,9}, Lili Deng¹, Amrita Singh Chandhoke¹, Chi Zhang², Azad Bonni^{2,3}, Shirin Bonni^{1*}

1 Southern Alberta Cancer Research Institute and Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada, **2** Department of Neurobiology, Harvard Medical School, Boston, Massachusetts, United States of America, **3** Department of Anatomy and Neurobiology, Washington University School of Medicine, St Louis, Missouri, United States of America

Abstract

Transforming growth factor-beta (TGF β) is a secreted polypeptide that plays essential roles in cellular development and homeostasis. Although mechanisms of TGF β -induced responses have been characterized, our understanding of TGF β signaling remains incomplete. Here, we uncover a novel function for the protein kinase NDR1 (nuclear Dbf2-related 1) in TGF β responses. Using an immunopurification approach, we find that NDR1 associates with SnoN, a key component of TGF β signaling. Knockdown of NDR1 by RNA interference promotes the ability of TGF β to induce transcription and cell cycle arrest in NMuMG mammary epithelial cells. Conversely, expression of NDR1 represses TGF β -induced transcription and inhibits the ability of TGF β to induce cell cycle arrest in NMuMG cells. Mechanistically, we find that NDR1 acts in a kinase-dependent manner to suppress the ability of TGF β to induce the phosphorylation and consequent nuclear accumulation of Smad2, which is critical for TGF β -induced transcription and responses. Strikingly, we also find that TGF β reciprocally regulates NDR1, whereby TGF β triggers the degradation of NDR1 protein. Collectively, our findings define a novel and intimate link between the protein kinase NDR1 and TGF β signaling. NDR1 suppresses TGF β -induced transcription and cell cycle arrest, and counteracting NDR1's negative regulation, TGF β signaling induces the downregulation of NDR1 protein. These findings advance our understanding of TGF β signaling, with important implications in development and tumorigenesis.

Citation: Pot I, Patel S, Deng L, Chandhoke AS, Zhang C, et al. (2013) Identification of a Novel Link between the Protein Kinase NDR1 and TGF β Signaling in Epithelial Cells. PLoS ONE 8(6): e67178. doi:10.1371/journal.pone.0067178

Editor: Srinivasa M. Srinivasula, IISER-TVM, India

Received: December 13, 2012; **Accepted:** May 14, 2013; **Published:** June 26, 2013

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: This work is supported by grants from the Alberta Cancer Foundation (ACF) and the Canadian Institutes of Health Research to S.B., a National Institutes of Health grant to A.B. (NS041021), Alberta Heritage Medical Foundation for Research (AHFMR) and ACF postdoctoral fellowships to I.P., and an ACF graduate studentship award to A.S.C. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: sbonni@ucalgary.ca

9 These authors contributed equally to this work.

Introduction

The transforming growth factor beta (TGF β) family of cytokines regulates a wide array of biological responses that are critical for proper development and homeostasis [1,2,3,4]. Deregulation of TGF β -mediated responses contributes to the pathogenesis of diverse disease processes from pulmonary and renal fibrosis to cancer [5,6,7,8,9]. A widely studied and key biological effect of TGF β is the inhibition of hematopoietic and epithelial cell proliferation [10,11,12,13], which has important consequences in cancer biology. Several types of carcinomas acquire resistance to TGF β -induced cell cycle arrest, leading to uncontrolled cell proliferation [10,11,12,13,14].

TGF β ligands form heteromeric complexes with type I and II transmembrane TGF β receptors, which have intrinsic serine/threonine kinase activities [15,16,17,18,19]. The type II kinase transphosphorylates the type I receptor in a glycine-serine rich motif, thereby stimulating the type I kinase activity [20,21,22]. The Smad family of intracellular signaling proteins is critical for transducing TGF β signals from the cell surface to the nucleus to regulate gene expression and consequent cellular processes [7,23,24]. In particular, the TGF β -stimulated type I receptors

associate and phosphorylate the receptor-regulated Smad (R-Smad) proteins Smad2 and Smad3 on the C-terminal two serine residues in the SSXS motif [23,24,25,26]. The phosphorylated R-Smads then form a heteromeric complex with the common partner Smad4, and the R-Smad/Smad4 complex accumulates in the nucleus and binds to specific binding elements within promoters of TGF β responsive genes [26,27,28]. The R-Smad/Smad4 complex acts together with other proteins to induce or repress transcription of responsive genes [29,30,31].

The transcriptional protein SnoN has emerged as a key regulator of TGF β signaling and responses [32,33,34,35]. SnoN associates with R-Smad2/3 and Smad4 and thereby regulates TGF β -induced transcription [36,37,38]. SnoN activates or represses TGF β -induced transcription, leading to divergent biological responses in a cell type- or context-dependent manner [33,34,39,40]. The critical role of SnoN in TGF β signaling suggests that identifying novel SnoN-associating proteins should enhance our understanding of TGF β responses.

NDR1 is a member of the evolutionary conserved NDR (nuclear Dbf2-related) family of serine-threonine kinases that form a subgroup of AGC kinases [41]. NDR1 and the closely related family member NDR2 regulate critical cellular processes including

cell proliferation, apoptosis and differentiation [42,43,44,45,46]. The expression of NDR kinases is deregulated in carcinomas including breast, lung and prostate cancer [47,48]. Interestingly, NDR kinases have been proposed to harbor positive or negative roles in tumorigenesis [47,48]. Whether these kinases regulate specific signaling pathways has remained largely unexplored [48].

Here, we identify NDR1 as a novel SnoN-interacting protein. We find that NDR1 inhibits TGF β -induced transcription and cell cycle arrest. NDR1 inhibits Smad2 phosphorylation, providing the basis for NDR1 regulation of TGF β responses. Remarkably, TGF β reciprocally promotes the degradation of NDR1, thereby providing a counterbalance to NDR1-inhibition of TGF β signaling. Collectively, our findings point to a novel and intimate link between the protein kinase NDR1 and TGF β signaling, with profound effects on the regulation of gene expression and cell proliferation.

Results

NDR1 Associates with the TGF β Signaling Protein SnoN

To gain new insights into the signaling mechanisms that control TGF β responses, we focused on identifying proteins that interact with SnoN, a key component in TGF β signaling. We used a tandem affinity purification (TAP) approach to immunopurify SnoN in human HaCaT keratinocytes, in which we stably expressed the double epitope-tagged version of SnoN (FLAG, HA-SnoN). To identify true SnoN associated proteins, we used cells expressing epitope-tagged SnoN at levels equivalent to those of endogenous SnoN (Figure 1A). Interestingly, stable expression of SnoN reduced the level of endogenous SnoN in these cells, further normalizing the level of SnoN between SnoN-expressing and control vector-transfected cells (Figure 1A, compare endogenous SnoN in lane 1 and exogenous SnoN in lane 3). Exposure of HaCaT cells to TGF β led to the downregulation of endogenous as well as stably expressed SnoN, suggesting that TGF β signaling behaves normally in HaCaT cells expressing epitope-tagged SnoN [37,38,49,50]. We performed tandem affinity purification (TAP) by sequential FLAG and HA immunoprecipitation of lysates of epitope-tagged SnoN-expressing HaCaT cells and control HaCaT cells followed by mass spectrometry of immunocomplexes [51,52]. SnoN and known SnoN-interacting proteins including Ski and Smad4 were immunopurified from SnoN-expressing cells, confirming the validity of the purification procedure (Table 1). We also identified novel SnoN-interacting proteins (Table 1). Among these proteins, we focused on the protein kinase NDR1 (also known as STK38).

NDR1 and its close relative NDR2 regulate several biological processes including cell proliferation, apoptosis and differentiation [42,43,44,45,46]. However, whether these kinases regulate specific growth factor signaling pathways has remained incompletely understood. Therefore, we further characterized the interaction of NDR1 with the TGF β signaling protein SnoN. In co-immunoprecipitation assays, we confirmed that SnoN and NDR1 formed a complex (Figure 1B, C). We next used the fusion of NDR1 or SnoN with the *Renilla* luciferase (Rluc) protein to assess the interaction of endogenous SnoN or endogenous NDR1, respectively, using *Renilla* luciferase activity as the readout [53]. We found that endogenous NDR1 robustly interacted with Rluc-SnoN (Figure S1A). Likewise, endogenous SnoN strongly interacted with Rluc-NDR1 (Figure S1B). Consistent with these results, endogenous NDR1 formed a complex with endogenous SnoN in the absence or presence of TGF β in 293T cells (Figure S1C). Together, these data suggest that NDR1 associates with SnoN in epithelial cells.

To gain further insight and evidence for the specificity of the SnoN-NDR1 association, we mapped the structural determinants of SnoN that are required for its interaction with NDR1 (Figure 1D). We used a series of Rluc-SnoN mutants in coimmunoprecipitation assays to enable quantitative assessment of the effect of mutations of SnoN on its interaction with expressed NDR1 in 293T cells. Removal of the N-terminal 96 amino acids did not affect SnoN's association with NDR1 (Figure 1E). Consistent with these results, the N-terminal 96 amino acids of SnoN failed to associate with NDR1. Interestingly, we found that deletion of amino acid residues 366–684 or 1–366 decreased significantly the ability of SnoN to interact with NDR1 (Figure 1E).

We also identified the regions in NDR1 that specify its association with SnoN (Figure 1F). We used the Rluc-NDR1 fusion and its mutants in these experiments. Deletion of the N-terminal 82 amino acid residues reduced the ability of NDR1 to associate with SnoN (Figure 1G). Interestingly, deletion of the C-terminal regulatory region alone or together with the N-terminal domain dramatically increased the ability of NDR1 to coimmunoprecipitate with SnoN (Figure 1G). Together, these data suggest that a region within the kinase domain specifies the association of NDR1 with SnoN, and the C-terminal regulatory region may interfere with the NDR1-SnoN interaction.

NDR1 Regulates TGF β -dependent Transcription

The finding that NDR1 associates with SnoN raised the important question of whether NDR1 regulates TGF β signaling. The plasminogen activator inhibitor 1 (PAI-1) is a TGF β -responsive immediate early gene that has been linked to the control of cell proliferation [40,54,55,56]. We characterized the role of NDR1 in TGF β -induced transcription employing the widely used 3TP-luciferase reporter gene containing TGF β -responsive promoter elements of the PAI-1 gene [56]. We first determined the effect of inhibition of endogenous NDR1 on TGF β -induced transcription. We used RNA interference (RNAi) to induce knockdown of endogenous NDR1 in epithelial cells. Two short hairpin RNAs (shRNAs) targeting distinct regions of NDR1 mRNA induced efficient knockdown of NDR1 protein in 293T cells (Figure S2A). Importantly, in reporter assays, knockdown of NDR1 using the two shRNAs singly or in combination significantly enhanced the ability of TGF β to induce expression of the 3TP-luciferase reporter gene in HaCaT keratinocytes (Figure 2A). Knockdown of NDR1 in NMuMG mammary epithelial cells with expression of NDR1 shRNAs also increased TGF β -induced 3TP-luciferase-reporter gene expression (Figure 2B). In complementary reporter assays, expression of NDR1 reduced in a dose-dependent manner the ability of TGF β to induce expression of the 3TP-luciferase gene in NMuMG cells (Figure S2B and Figure 2C). Similarly, NDR1 repressed the ability of TGF β to induce the expression of the 3TP-luciferase reporter gene in HaCaT cells (Figure 2D). Thus, based on knockdown and gain of function analyses, we conclude that NDR1 inhibits the ability of TGF β to induce transcription.

We next characterized the role of NDR1 in the regulation of TGF β -induced expression of the endogenous PAI-1 gene. As expected, TGF β stimulation of control-transfected NMuMG cells increased the abundance of endogenous PAI-1 mRNA as assessed by quantitative real time PCR. Knockdown of endogenous NDR1 in NMuMG cells significantly enhanced the ability of TGF β to increase the abundance of PAI-1 mRNA (Figure 3A). We also measured the ability of TGF β to induce PAI-1 expression in NMuMG cells stably expressing wild type NDR1 (WT) or a kinase-inactive version of NDR1 in which Lysine 118 was mutated to arginine (KR) (Fig. 3B). The expression of wild type NDR1




Figure 1. NDR1 is a novel SnoN-interacting protein. **A.** Lysates of untreated or TGFβ-treated HaCaT cells expressing FLAG, HA-SnoN or control vector were immunoblotted with the SnoN or actin antibody. TGFβ similarly reduced the abundance of endogenous and exogenous SnoN in HaCaT cells. **B.** Lysates of 293T expressing MYC-SnoN alone or together with HA-NDR1 were subjected to immunoprecipitation with the HA antibody followed by immunoblotting with the SnoN or HA antibody. Total lysates were also subjected to immunoblotting with the SnoN or actin antibody, the latter to serve as a loading control. **C.** Lysates of 293T cells expressing HA-NDR1 alone or together with MYC-SnoN were subjected to immunoprecipitation with the SnoN antibody followed by immunoblotting with the HA or SnoN antibody. Lysates were also immunoblotted with the HA or actin antibody. NDR1 formed a complex with SnoN. **D.** A schematic diagram showing the wild type (amino acid (aa) 1–684) and four deletion mutants of SnoN. The dotted area represents the ski/sno/dac (DACH) domain, the shaded area the SAND domain, and the striped areas the helical dimerization domains [33]. **E.** Lysates of 293T cells expressing Rluc in fusion with wild type or a series of SnoN mutants, as shown in D, alone or together with HA-NDR1 were subjected to immunoprecipitation with the HA antibody followed by luciferase assays to determine the levels of Rluc-SnoN fusion proteins in the NDR1 immunoprecipitates. Aliquots of cell lysates were also assayed for luciferase activity as a measure of Rluc-SnoN expression. The expression of HA-NDR1 in aliquots of immunoprecipitates (10%) and cell lysates was confirmed by immunoblotting using the HA antibody (data not shown). NDR1-associated Rluc-SnoN luciferase activity was normalized to Rluc-SnoN and NDR1 expression. Data are presented as the mean±SEM (n = 4) of NDR1-associated Rluc activity relative to Rluc activity associated with NDR1 in the case of the wild type Rluc-SnoN fusion protein. **F.** A schematic diagram showing the wild type (aa1–465) and three deletion mutants of NDR1. The dotted area represents the N-terminal regulatory domain, the shaded area the kinase domain, and the striped area the C-terminal regulatory domain. **G.** Lysates of 293T cells expressing Rluc in fusion with wild type or a series of NDR1 mutants, as in F, alone or together with MYC-SnoN, were subjected to immunoprecipitation using the MYC or SnoN antibody. Immunoprecipitates and cell lysates were subjected to luciferase assays, SnoN immunoblotting (Data not shown), and data analyses as described in E. Data are presented as the mean±SEM (n = 7) of SnoN-associated Rluc activity expressed relative to SnoN-associated Rluc activity in the case of wild type NDR1-Rluc. *, or *** indicates significant difference as compared to wild type SnoN-Rluc (E) or NDR1-Rluc (G) at p<0.05 or p<0.001, respectively (ANOVA). doi:10.1371/journal.pone.0067178.g001

blocked TGFβ-induced PAI-1 mRNA expression in NMuMG cells (Figure 3C). In contrast, the kinase-inactive NDR1 enhanced the ability of TGFβ to increase the abundance of PAI-1 mRNA (Figure 3C). These data suggest that the kinase-inactive NDR1

enhanced TGFβ-induced PAI-1 gene expression by acting in a dominant negative fashion to block the ability of endogenous NDR1 to antagonize TGFβ-induced transcription. Together,

Table 1. Mass spectrometry data of SnoN-interacting proteins in HaCaT cells.

Identified protein ^{a,b}	gi number	Mass	Score ^c	Number of peptides matched	Ion score range
<i>Gel slice 1</i>					
SnoN	4885599	76955	137	10	7–69
RBM10	12644371	103396	80	4	6–63
Ski	4506967	79955	64	5	21–49
<i>Gel slice 2</i>					
SnoN	4885599	76955	214	19	8–68
Skb1Hs/PRMT5 ^d	232410	72740	161	12	2–82
STK38/NDR1	6005814	54155	115	9	17–52
PTP1B ^d	4505995	52609	106	8	4–53
Smad4	4885457	60401	104	12	5–62
α -tubulin	340021	50120	87	3	17–68
<i>Gel Slice 3</i>					
No significant hits					

^aIdentified proteins represent peptides only present in the SnoN-expressing samples, and not in the control cells.

^bTrypsin, immunoglobulin and keratin are considered contaminants and are omitted from this list.

^conly identified proteins with a score of ≥ 50 are shown here.

^dThese identified proteins were also present in the control cells, but the number of peptides matched and overall score was much lower in the control cells than in the SnoN-expressing samples.

doi:10.1371/journal.pone.0067178.t001

these data suggest that NDR1 acts in a kinase-dependent manner to negatively regulate TGF β -induced transcription.

NDR1 Antagonizes TGF β -induced Cell Cycle Arrest

The finding that NDR1 inhibits TGF β -induced gene expression led us to ask whether NDR1 might also impact biological processes regulated by TGF β . NMuMG cells undergo growth arrest in response to TGF β stimulation [57]. We analyzed the growth rate curves of NMuMG cells stably expressing wild type NDR1 or kinase-inactive NDR1 protein (KR). Cells were plated and left untreated or incubated with TGF β and counted after one, two or three days (Figure 4A, B). As expected, TGF β reduced the population growth of control-transfected cells (Figure 4A, B). However, expression of wild type but not the kinase-inactive NDR1 significantly inhibited the ability of TGF β to suppress the population growth of NMuMG cells (Figure 4A, B). These data suggest that NDR1 impairs TGF β -induced cell cycle arrest in a kinase-dependent manner. NDR1 similarly opposed TGF β suppression of population growth of NMuMG cells when we employed automated cell counts using the Cellomics KSR instrument whereby NMuMG cells were labeled with the DNA dye bisbenzimidazole (Hoechst) (Figure S3A). To determine if NDR1 regulates the ability of TGF β to control cell proliferation, we performed BrdU incorporation assays (Figure 4C). As expected, TGF β markedly reduced the ratio of BrdU-labeled cells, suggesting that TGF β induces cell cycle arrest in NMuMG cells (Figure 4D). The expression of wild type NDR1, but not kinase-inactive NDR1, opposed TGF β -suppression of BrdU incorporation in NMuMG cells (Figure 4C, D).

In complementary studies, we found that knockdown of NDR1 enhanced the potency of TGF β to induce 50% reduction in the population growth of NMuMG cells (EC50) (Figure 4E, F and Figure S3B, C). Interestingly, knockdown of NDR1 together with knockdown of the closely related protein NDR2 further enhanced the potency of TGF β to induce cell cycle arrest in NMuMG cells (Figure 4E, F, Figure S3C). Collectively, our data suggest that NDR1 antagonizes the ability of TGF β to inhibit cell proliferation.

NDR1 Suppresses TGF β -dependent Smad2 Phosphorylation

The ability of NDR1 to oppose TGF β -dependent transcription and cell cycle arrest raised the question of the mechanism by which NDR1 exerts this effect. TGF β -dependent phosphorylation and consequent nuclear accumulation of the receptor-regulated Smad proteins mediate TGF β -induced transcription and biological responses. We, therefore, determined the effect of NDR1 on the phosphorylation and nuclear accumulation of Smad2 in NMuMG cells upon exposure to TGF β . As expected, TGF β robustly increased the phosphorylation of Smad2 (Figure 5A, B). Strikingly, we found that wild type NDR1 substantially reduced the ability of TGF β to induce Smad2 phosphorylation in NMuMG cells (Figure 5). Consistent with these results, wild type NDR1 suppressed TGF β -induced accumulation of Smad2 in the nucleus in NMuMG cells (Figure S4). By contrast to wild type NDR1, expression of the kinase-inactive NDR1 (KR) enhanced TGF β -induced phosphorylation and nuclear accumulation of Smad2 in NMuMG cells (Fig. 5 and Fig. S4). Together, these data suggest that NDR1 inhibits the ability of TGF β to trigger the phosphorylation and consequent nuclear accumulation of Smad2 and thereby impairs TGF β -induced transcription.

TGF β Signaling Induces NDR1 Degradation

The identification of NDR1 as a negative regulator of TGF β -induced transcription and cell cycle arrest raised the important question of whether TGF β signaling might in turn influence NDR1. We characterized the effect of TGF β on the abundance of endogenous NDR1 in NMuMG cells. Remarkably, we found that TGF β stimulation reduced the steady-state levels of NDR1 (Figure 6A, B). Incubation of cells with the TGF β -type I kinase inhibitor SB431542 (T β RI-KI) restored the abundance of NDR1 protein in TGF β -treated cells (Figure 6A, B). Using quantitative real-time RT-PCR analyses, we found that TGF β did not reduce and instead increased the abundance of NDR1 mRNA, suggesting that TGF β -induced downregulation of NDR1 protein is not due to changes in NDR1 gene expression (Figure 6C).




Figure 2. NDR1 inhibits TGF β -induced transcription. **A.** Lysates of untreated or TGF β -treated HaCaT cells transfected with the TGF β -responsive 3TP-*Firefly* luciferase reporter and *CMV-Renilla*-luciferase reporter, as a transfection efficiency control, together with the control RNAi vector (-), or NDR1 RNAi NDR1i-1, NDR1i-2 plasmid alone or together, were subjected to dual luciferase assays. Data are presented as the mean+SEM (n = 4) of normalized-3TP-luciferase activity expressed relative to that of the untreated control. **B.** Lysates of NMuMG cells transfected with reporters as in A together with the control RNAi plasmid or the NDR1i-2 plasmid, and analyzed as in A. Data are presented as the mean+SEM (n = 3) of luciferase activity expressed relative to the untreated control. **C.** Lysates of untreated or TGF β -treated NMuMG cells transfected with reporters as in A, together with a control vector (-) or increasing concentrations of an NDR1 expression plasmid, were subjected to dual luciferase assays and data analysis as in A. **D.** Lysates of untreated or TGF β -treated HaCaT cells transfected as described for NMuMG cells in C except for using the *CMV- β* -galactosidase expression plasmid as a transfection efficiency reporter, were subjected to luciferase and β -galactosidase assays. For each experiment, luciferase activity was normalized as in A. Data in C and D are presented as the mean+SEM (n = 5) of 3TP-luciferase activity expressed relative to the untreated control. *, **, or *** indicates significant difference from the TGF β -treated control at $p < 0.05$, $p < 0.01$, or $p < 0.001$, respectively (ANOVA). doi:10.1371/journal.pone.0067178.g002

We next considered the possibility that the downregulation in NDR1 protein in response to TGF β might result from the increased turnover of NDR1 protein. We measured the rate of NDR1 protein turnover in NMuMG cells treated for different times with the protein synthesis inhibitor cycloheximide in the absence (-) or presence (+) of TGF β (Figure 6D, E). We found that the half-life of NDR1 in control cells was greater than 16 h, suggesting that NDR1 is a relatively stable protein. Stimulation of cells with TGF β reduced the half-life of NDR1 to approximately 8 h, suggesting that TGF β increased the turnover of NDR1 (Figure 6D, E). To further explore the decrease in steady-state levels of NDR1 by long-term activation of TGF β signaling (Figure 6A, B), we assessed NDR1 turnover rates in cells that were left untreated or pretreated with TGF β for 24 h prior to the time-

course treatment of cycloheximide. Interestingly, we found that pretreatment of cells with TGF β led to eight-fold reduction in the half-life of NDR1, suggesting that prolonged TGF β treatment induced substantial degradation of NDR1 (Figure 6F, G). Using *in vivo* ubiquitination assays, we found that NDR1 was conjugated with ubiquitin in 293T cells (Fig. 6H and Figure S5) [49]. Importantly, expression of a constitutively active TGF β type I receptor, which activates the Smad signaling pathway in the absence of TGF β addition [21], robustly stimulated the ubiquitination of NDR1 in cells (Figure 6H and Figure S5A). We also found that exposure of 293T cells to the proteasome inhibitor MG132 suppressed the ability of TGF β to reduce the abundance of NDR1 (Figure 6I and Figure S5B). Together, these data suggest that TGF β signaling induces NDR1 ubiquitination and its




Figure 3. NDR1 represses TGF β -induction of endogenous PAI-1 gene expression. **A.** RNA extracts of untreated or TGF β -treated NMuMG cells transfected with a control RNAi plasmid or the combination of NDR1i-1 and NDR1i-2 RNAi plasmids were subjected to quantitative RT-PCR to determine the abundance of PAI-1 mRNA, where GAPDH mRNA was used as an internal control. Data are presented as the mean+SEM (n=5) of GAPDH-normalized PAI-1 mRNA abundance relative to untreated control. **B.** Lysates of NMuMG cells expressing FLAG-tagged wild type NDR1 (WT) or kinase-inactive NDR1 in which Lysine 118 is mutated to arginine (KR), or vector control were subjected to immunoblotting using the NDR1 or actin antibody, with the latter serving as a loading control. **C.** RNA extracts from untreated or TGF β -treated NMuMG cells expressing wild type or kinase-inactive NDR1 or the vector control were subjected to quantitative RT-PCR analysis of PAI-1 and GAPDH mRNA as described in A. Data are presented as the mean+SEM (n=3) of relative GAPDH-normalized PAI-1 mRNA abundance as in A. *, **, or *** indicates significant difference from the TGF β -treated control at p<0.05, p<0.01, or p<0.001, respectively (ANOVA). doi:10.1371/journal.pone.0067178.g003

consequent degradation involving the 26S proteasome (Figure 6H, I and Figure S5A, B).

Collectively, our study identifies an important functional and regulatory link between NDR1 and the TGF β signaling pathway.

NDR1 suppresses TGF β -induced transcription and cell cycle arrest, and to overcome this effect, TGF β promotes the ubiquitination and turnover of NDR1.

Discussion

In this study, we have discovered a critical role for the protein kinase NDR1 in the regulation of TGF β signaling in proliferating cells. We have identified NDR1 as a novel interacting protein with SnoN, a key component of the TGF β signaling pathway. Loss and gain of function analyses reveal that NDR1 suppresses TGF β -induced transcription and cell cycle arrest in epithelial cells. NDR1 inhibits the ability of TGF β to induce the phosphorylation and consequent nuclear accumulation of Smad2, providing the mechanistic basis for NDR1 regulation of TGF β -induced transcription and cellular responses. Remarkably, we have also found that TGF β reciprocally regulates NDR1, triggering the degradation of NDR1. These findings define an intimate link between NDR1 and TGF β signaling, whereby NDR1 inhibits TGF β -induced transcription and cell cycle arrest, and to counteract this effect, TGF β enhances the turnover of NDR1 protein (Figure 7).

The finding that NDR1 antagonizes TGF β -induced cell cycle arrest in epithelial suggests that cancer cells may employ an NDR1-dependent mechanisms to evade the tumor suppressive effect of TGF β . Consistent with this possibility, we have found that knockdown of NDR1 restores the ability of TGF β to induce cell cycle arrest in the human breast MDA-MB-231 carcinoma cells, which are resistant to the TGF β -induced cell cycle arrest (Figure S6A, B, C). Thus, deregulation of NDR1 control of TGF β signaling may be relevant in cancer pathogenesis.

The identification of NDR1 as a novel regulator of TGF β -induced transcription advances our understanding of the mechanisms that control TGF β responses. We have found that NDR1 markedly inhibits TGF β -induced cell cycle arrest. In future studies, it will be interesting to determine whether NDR1 modulates other TGF β responses including epithelial-mesenchymal transition, extracellular remodeling, and cell migration, or whether NDR1 specifically regulates cell proliferation.

How does NDR1 inhibit TGF β -induced transcription and cell cycle arrest? We have found that NDR1 strongly inhibits the phosphorylation and the nuclear accumulation of Smad2. The inhibition of Smad2 phosphorylation provides a basis for NDR1-inhibition of TGF β -induced transcription and cell cycle arrest. Recent studies suggest that the protein kinase Iats, which is related to NDR1, restricts the nuclear accumulation of Smad2 without affecting its phosphorylation [58]. Thus, NDR1 and Iats employ distinct mechanisms to regulate TGF β signaling. How NDR1 inhibits Smad2 phosphorylation remains to be characterized. Since the kinase activity of NDR1 is required for its ability to inhibit Smad2 signaling, it will be critical in future studies to identify substrates of NDR1 that lead to the inhibition of Smad2 phosphorylation.

The finding that TGF β triggers the degradation of NDR1 proteins suggests that reciprocal negative feedback regulation of NDR1 and TGF β signaling provides balance in their mutually opposing effects. Intriguingly, TGF β induces the degradation of SnoN, which as we have found in this study interacts with NDR1. The E3 ubiquitin ligases Cdh1-APC, Smurf2, and Arkadia mediate the TGF β -induced ubiquitination and consequent degradation of SnoN [49,50,59,60,61]. In future studies, it will be interesting to determine if these E3 ubiquitin ligases or others induce the ubiquitination of NDR1 in cells upon exposure to TGF β .




Figure 4. NDR1 suppresses TGFβ-repression of cell proliferation. **A.** Population growth curves of NMuMG cells expressing wild type (WT) or kinase-inactive (KR) NDR1 or the vector control (-) analyzed using phase-contrast microscopy after one, two or three days of culturing in the absence (solid lines) or presence (broken lines) of TGFβ. Each point is the mean ± SEM (n = 7) of cell population normalized to cell population seeding. **B.** The effect of TGFβ on cell population growth curves for NMuMG expressing NDR1 or the vector control as in A was analyzed as the difference of untreated and TGFβ-treated cell populations as a percent of untreated cell counts. Each point is the mean ± SEM (n = 7) of the percent decrease in

population growth by TGF β . **C.** Representative fluorescence microscopy images of untreated or 48h-TGF β -treated NMuMG cells expressing wild type or kinase-inactive NDR1 or the vector control that were incubated for 1 h with bromodeoxyuridine (BrdU) and subjected to indirect immunofluorescence using the BrdU antibody and a Cy2-conjugated secondary antibody (green), and labeling with the DNA Hoechst dye (blue) **D.** For each cell type as in C, percent reduction of BrdU-labeled cells in response to TGF β was quantified as in B. Data are presented as the mean+SEM (n=3) of the percent reduction in BrdU incorporation in cells in response to TGF β . **E.** Representative fluorescence images of GFP-expressing (green) and DNA dye (Hoechst) (blue)-labeled NMuMG cells transfected with control RNAi plasmid or the combination of NDR1i-1 and NDR1i-2 (NDR1i) RNAi plasmids alone or together with the combination of NDR2i-1 and NDR2i-2 RNAi (NDR2i) plasmids, and incubated one day post transfection with 0, 5, 20 and 100 pM TGF β for 36 h. **F.** A target activation algorithm accompanying the Cellomics KSR instrument used to capture images including those shown in E was used to determine population growth of GFP-positive cells in 96 well plates. For each experiment, triplicate average population growth of GFP-positive cells was plotted versus TGF β concentration and fitted using log transformation to obtain the effective concentration of TGF β leading to 50% reduction of population growth of GFP-expressing cells (EC50). Data are presented as the mean+SEM of EC50 values expressed relative to the NMuMG cells transfected with the vector control from six (- and NDR1i) or five (NDR1i) independent experiments. The width of each fluorescence micrograph in C and E corresponds to 330 μ M. **, or *** indicates significant difference from the control at p<0.01, or p<0.001, respectively (ANOVA).

doi:10.1371/journal.pone.0067178.g004

Although we have focused our studies on the identification of NDR1 as a novel regulator of TGF β signaling in proliferating cells, our findings may have broader implications for both TGF β signaling and NDR1. In the developing mammalian nervous system, TGF β -Smad2 signaling has been implicated in the control

of axon development, whereby Smad2 inhibits axon growth in granule neurons of the rat cerebellar cortex [62]. In view of our finding demonstrating that NDR1 inhibits Smad2 signaling, it will be interesting to determine whether NDR1 promotes axon growth in mammalian neurons. Conversely, recent studies have revealed that NDR1 controls the development of dendrites and synapses in mouse hippocampal neurons [46]. Our finding that TGF β induces the degradation of NDR1 raises the interesting question of whether TGF β might influence these aspects of neuronal morphogenesis.

Our findings have implications beyond cellular development and homeostasis. Since loss of responsiveness to TGF β -induced cell cycle arrest contributes to tumorigenesis [10,11,12,13,14], the identification of a novel role for NDR1 in TGF β signaling suggests that NDR1 may also influence tumor initiation. Notably, NDR1 is upregulated in lung and mammary carcinomas [47,48], raising the possibility that NDR1 might contribute to loss of TGF β responsiveness in these tumors. Thus, our study raises the potential for NDR1 as a target for drug discovery in cancer biology.




Figure 5. NDR1 impairs TGF β -phosphorylation of Smad2. A. Lysates of untreated or 48h-TGF β -incubated NMuMG cells transfected with an expression plasmid encoding wild type or kinase-inactive NDR1, or transfected with the vector control were subjected to immunoblotting using an antibody that recognizes Smad2 when phosphorylated specifically at the TGF β -induced sites (pSmad2) or an antibody that recognizes Smad2 regardless of its phosphorylation status (Smad2) or with an actin antibody, the latter serving as a loading control. **B.** Actin-normalized TGF β -phosphorylated Smad2 was expressed relative to the actin-normalized total Smad2. Data are presented as the mean+SEM (n=3) ratio of TGF β -phosphorylated Smad2 to total Smad2. Statistical significance between TGF β -induced phosphorylation of Smad2 in the vector control cells and each of the wild type and kinase-inactive NDR1-expressing cells is indicated (ANOVA). doi:10.1371/journal.pone.0067178.g005

Materials and Methods

Plasmids

A pCaGiP vector was used to generate FLAG, HA double epitope-tagged SnoN or FLAG epitope-tagged NDR1 stable expression constructs, where a bicistronic transcript containing an internal ribosomal entry site (IRES) encoded the puromycin resistance marker and the protein of interest [39,63,64]. FLAG, HA-tagged SnoN containing nucleotides to express FLAG, Tobacco Etched Virus (TEV) protease site (ENLYFQG), and HA peptides upstream of the SnoN cDNA was generated using a polymerase chain reaction (PCR)-based cloning approach. Expression vectors to express fusion proteins of *Renilla* luciferase (Rluc) with wild type or deletion mutant SnoN were generated by PCR-based amplification and subcloning of the Rluc cDNA upstream of SnoN cDNA in CMV-based (pCMV5B) SnoN-expression vectors [37,49,50,65]. The NDR1 cDNA product of PCR amplification of epithelial cell-derived polyA-cDNA using NDR1 gene-specific oligonucleotides was used to generate HA- and FLAG-tagged NDR1 expression vectors (pCMV5B and pCaGiP). Constructs expressing Rluc in fusion with wild type or deletion mutant NDR1 were generated as described for Rluc-SnoN. NDR1 and NDR2 RNA interference (RNAi) plasmids were constructed using the pU6/CMV/enhanced green fluorescent protein (GFP) expression control vector, with NDR1 or NDR2 shorthairpin RNAs (shRNAs), and GFP under the control of U6 and CMV promoters, respectively [40]. Two shRNAs-expressing constructs were generated to target distinct regions in each of NDR1 and NDR2 mRNAs as follows: NDR1i-1, 5'GCAACCT-TATCGCTCAACAT3', NDR1i-2, 5'GGCAGA-




Figure 6. TGFβ signaling promotes NDR1 turnover. **A.** Lysates of untreated or 48h-TGFβ-treated NMuMG cells in the absence or presence of the TGFβ type I receptor kinase inhibitor SB431542 (KI) were subjected to immunoblotting with the NDR1 or actin antibody. **B.** Protein abundance of NDR1 and actin in immunoblots, including those shown in A, were quantified and percent reduction of NDR1 (normalized to actin) in response to TGFβ was analyzed. Data are presented as the mean±SEM (n=4) of percent decrease in protein abundance of NDR1 in NMuMG cells in response to TGFβ. TGFβ treatment decreased the protein abundance of NDR1 in NMuMG cells. **C.** TGFβ does not repress NDR1 mRNA expression. RNA extracts from untreated or 48h-TGFβ-treated NMuMG cells were analyzed by quantitative RT-PCR for NDR1 and GAPDH mRNA abundance. Data are presented as the mean±SEM (n=3) of relative mRNA abundance of NDR1 in NMuMG cells. TGFβ did not reduce relative abundance of NDR1 mRNA. Significant

differences are indicated in B and C as determined by unpaired, two-tailed t-test. **D.** Lysates of NMuMG cells left untreated or incubated with 10 μg/ml cycloheximide for different times, alone or together with 100 pM TGFβ, were subjected to immunoblotting using the NDR1 or actin antibody. **E.** Protein abundance of NDR1 in immunoblots, including the one shown in Figure 6D, were quantified and normalized to actin. Data are presented as the mean ± SEM (n = 3) of normalized protein abundance of NDR1 expressed relative to that at time 0 for the respective minus or plus TGFβ group. Data interpolation indicated that NDR1's half-life was greater than 16 h. TGFβ reduced NDR1's half-life to approximately 9 h. **F.** Lysates of untreated or 24 h-TGFβ-preincubated NMuMG cells followed by exposure to cycloheximide for different time points, were subjected to immunoblotting using NDR1 or actin antibody. **G.** Protein abundance of NDR1 in immunoblots as described and including the one shown in Figure 6F was quantified as described in E. Data are presented as the mean ± SEM (n = 4) of relative NDR1 levels. TGFβ reduced the half-life of NDR1 from greater than 16 h to approximately 2.5 h. **H.** TGFβ signaling enhances the ubiquitination of NDR1. Lysates of 293T cells expressing FLAG-NDR1, HA-ubiquitin, and constitutively active TGFβ type I receptor, were subjected to immunoprecipitation using the FLAG antibody, followed by immunoblotting with the HA or NDR1 antibody. Cell lysates were also immunoblotted with the FLAG or actin antibody. HC refers to the heavy chain of the FLAG antibody. **I.** Lysates of 293T cells transfected with FLAG-NDR1 alone or together with constitutively active TGFβ type I receptor and treated without or with 0.5 μM MG132 (Sigma) for 7 hours were subjected to immunoblotting with the FLAG or actin antibody. *, **, or *** in E and G indicates significant difference from respective control at P < 0.05, p < 0.01, or p < 0.001, respectively (ANOVA). # indicates significant difference from control (p < 0.05, unpaired, one tailed t-test).

doi:10.1371/journal.pone.0067178.g006

CAGTTTGTGGGT TGT3', NDR2i-1, 5'GGAGGTGACATGATGACATT3', and NDR2i-2, 5'GCAGACTG GTTACAA-CAAATT3'. All constructs were verified by restriction digests and DNA sequencing analysis (University of Calgary Core Sequencing Facility).

Cell Cultures and Transfections

The human keratinocyte HaCaT [66], embryonic kidney 293T [67,68], and mouse mammary gland epithelial NMuMG [69,70,71] cells were obtained from ATCC and maintained in appropriate growth conditions [39,40,63,72]. The human breast carcinoma MDA-MB-231 cells, a generous gift from Dr. Frank Jirik, were maintained in Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum [73,74]. 293T cells were transfected using the calcium phosphate method [40]. HaCaT cells were transiently transfected using *Fugene* (Roche), *TransIT-LT1* reagent (Mirus), or Lipofectamine-LTX (Invitrogen) according to the manufacturer's instructions. HaCaT cells were transfected with the pCAGiP vector (vector control) or one encoding the FLAG, HA-SnoN using Lipofectin (Invitrogen) and incubation in 0.45 μg/ml puromycin (Invitrogen)-containing medium for selection of control vector or SnoN stably expressing cells. A similar strategy was used to generate control and FLAG-NDR1 expressing NMuMG cells with the exception of using 2 μg/ml puromycin. MDA-MB-231 were transfected using Lipofectamin and plus reagents (Invitrogen).

Immunoprecipitations, Immunoblottings, and TAP

Cells were lysed in TNE-based buffer-containing 0.5% Triton X-100, protease and phosphatase inhibitors, and lysates were cleared by centrifugation and subjected to protein concentration determination using the Bradford protein assay (BioRad)

[39,40,63,75]. For interaction studies, equivalent amounts of protein, representing a maximum of approximately 90% of total protein content per sample, were subjected to immunoprecipitations using appropriate antibodies. Immunoprecipitates and aliquots of the lysates were subjected to immunoblottings or *Renilla* luciferase assays using the *Renilla* luciferase kit (Promega) and the Orion II luminometer (Berthold Detection Systems) detection system. Immunoprecipitates-containing RLuc-fusion proteins (or RLuc protein alone) were resuspended in TNE buffer containing 0.1% Triton X-100 prior to measuring any associated luciferase activity [53]. Antibodies used in the immunoprecipitations and immunoblottings included rabbit anti-SnoN (H317, Santa Cruz), mouse anti-Flag (M2, Sigma), mouse anti-Myc (9E10, Covance), mouse anti-HA (16B12, Covance), rabbit anti-Actin (Sigma), mouse anti-NDR1 (2G8-1F3, Abnova), rabbit anti-NDR1 (H100, Santa Cruz), mouse anti-Smad2/3 (BD-Transduction laboratories), rabbit anti-phospho (Ser465/467) Smad2 (Calbiochem), and horseradish peroxidase-conjugated anti-mouse and anti-rabbit IgG antibodies (GE healthcare). Immunoblotting-generated enhanced chemiluminescence signals were visualized and quantified using a Versadoc 5000 Imager (Bio-Rad) and Quantity One software, respectively [39,40,63,75]. For tandem affinity purification (TAP) experiments, lysates of FLAG, HA-SnoN-expressing HaCaT cells or vector control-transfected HaCaT cells were subjected to immunoprecipitation using anti-FLAG[®] M2 antibody affinity gel (Sigma), elution of immunocomplexes by treatment with TEV enzyme, immunoprecipitation of the eluate with anti-HA affinity matrix (Roche), and partial separation of immunoprecipitates by SDS-PAGE. Processing and analysis of colloidal Coomassie-stained gel slices was performed at the Southern Alberta Mass Spectrometry (SAMS) Centre for Proteomics by LC-MS/MS [51,52].




Figure 7. A schematic model showing that SnoN and NDR1 interact, and that NDR1 and TGFβ reciprocally inhibit each other in epithelial cells.

doi:10.1371/journal.pone.0067178.g007

Luciferase Reporter Assays

HaCaT and NMuMG cells were seeded at 2.5 to 3.5×10^4 cells/well in 24-well plates. Cells were co-transfected with the 3TP-*Firefly* luciferase reporter constructs, the CMV-β-galactosidase or pR-TK *Renilla* luciferase internal control reporter constructs, together with a control vector or one encoding an NDR1 protein, or with a control or NDR1 RNAi vector, incubated for 16 to 18 h in 0.2% fetal bovine serum-containing medium in the absence or presence of 100 pM TGFβ (R & D Systems, Minneapolis, MN), lysed and subjected to single or dual luciferase activity assays [39,40,63,72,75], with each experimental condition carried out in triplicates. Each replicate's arbitrary *Firefly* luciferase activity, in relative light units, was normalized to its β-galactosidase or *Renilla*-luciferase activity, to control for variations in transfection efficiency.

Quantitative Real Time PCR

DNase-treated TRIzol (Gibco)-extracted RNA from NMuMG cells cultured in the absence or presence TGF β was reverse transcribed using SuperScript II transcriptase (Invitrogen) and oligo-(dT)₁₂₋₁₈ (Amersham Biosciences) [40,63,75,76]. The polyA-cDNAs were subjected to quantitative PCR using gene-specific primers for Plasminogen Activator Inhibitor 1 (forward-5'TCTCAGAGGTGGAAAGAGCCAG3', reverse-5'TGAAGTAGAGGGCATTACCAGC3'), NDR1 (forward-5'ATTTGGTGAGGTACGGCTTG3' and reverse-5'CAGGCAGGAACTCCA TGATT3'), and the house-keeping gene glyceraldehyde-3-phosphate dehydrogenase (forward-5'TCAA-CAGCAACTCCCCTCTTCCA3' and reverse-5'AC-CCTGTTGCTGTAGCCGTATTC A3') using a 2X Sybr Green Mix (BioRad) and Rotor-Gene Thermocycler (Corbett Research). The specificity of the products was confirmed using the melt curve method. Data were analyzed and expressed as described [75].

Microscopy and Cell Proliferation Assays

For fluorescence microscopy experiments, NMuMG cells left untreated or incubated with TGF β for two days were formaldehyde-fixed, and incubated with DNA dye bisbenzimidazole (Hoechst) (Invitrogen). For indirect Smad2/3 immunofluorescence, untreated or TGF β -treated NMuMG cells were incubated with a mouse Smad2/3 antibody, and a Cy3-labelled anti-mouse antibody (Jackson Laboratories) in the presence of the DNA dye Hoechst. Images of cells were captured using a Kinetic Scan Reader (KSR) (Cellomics, Inc., Pittsburgh, PA) equipped with a Carl Zeiss Axiom x microscope and a charge-coupled device (CCD) digital camera [39,63]. Bromodeoxyuridine (BrdU) assays were carried out using a BrdU assay kit (Roche), fluorescence images were captured using fluorescence microscopy, and data were generated using the Target Activation Bio-Application of the Cellomics KSR [39]. For cell growth rates analyses, cells were grown for one, two or three days in the presence or absence of 100 pM TGF β , and counted using a haemocytometer prior to and at each day during treatment. Alternatively, population cell growth was determined based on nuclei counts in fixed cells stained with the DNA dye Hoechst. Cell counts were normalized to cell numbers before treatment, and replicate values were averaged. For RNAi assays, NMuMG or MDA-MB-231 cells were transfected with GFP-expressing plasmids containing an RNAi control vector, or the NDR1 shRNAs alone or together with NDR2 shRNA expressing vectors as described in the legends of Figure 4, Figure S3, and Figure S6. Untreated or TGF β -incubated NMuMG or MDA-MB-231 cells were fixed and incubated with the DNA dye Hoechst 36 h after ligand treatment. Cells were identified by GFP (green) and nuclei (Hoechst) (blue) fluorescence signals, and the number of GFP-positive cells was assayed using the Target Activation Bio-Application of the Cellomics KSR instrument. Data were analyzed as described in figure legends.

Statistical Analysis

Data were subjected to Analysis of Variance (ANOV) or student t-test as indicated in the figure legends with significant difference set at $p < 0.05$.

Supporting Information

Figure S1 Related to Figure 1. A. Lysates of 293T cells expressing *Renilla* luciferase (Rluc), alone, or as fusion with SnoN (Rluc-SnoN) were subjected to immunoprecipitation using the NDR1 antibody or IgG immunoglobulins, as a negative control, followed by analysis of immunoprecipitates by luciferase assays

(90%) or immunoblotting (10%) with NDR1 antibody (data not shown). Cell lysates were also analyzed by luciferase assays and immunoblotting using NDR1 or actin antibody (data not shown). Endogenous NDR1-associated Rluc or Rluc-SnoN luciferase (IgG-subtracted) were normalized to Rluc or Rluc-SnoN, respectively, and endogenous NDR1 expression. The data are presented as the mean \pm SEM ($n = 3$) of NDR1-associated Rluc activity relative to Rluc activity associated with NDR1 in the case of the Rluc control. Rluc-SnoN associated robustly with endogenous NDR1. **B.** Lysates of 293T cells expressing Rluc or Rluc-NDR1 were subjected to immunoprecipitation using a SnoN antibody or IgG immunoglobulins, as a negative control, followed by analysis of the immunoprecipitates by luciferase assays (90%) or immunoblotting (10%) with SnoN antibody (data not shown). Cell lysates were also subjected to luciferase assays or immunoblotting with SnoN or actin antibody (data not shown). Endogenous SnoN-associated Rluc or Rluc-NDR1 activity was determined as in A. Data are presented as the mean \pm SEM ($n = 4$) of SnoN-associated Rluc activity relative to Rluc activity associated with SnoN in the case of the Rluc control. Rluc-NDR1 interacted strongly with endogenous SnoN. **C.** Lysates of untreated or TGF β -treated 293T cells were subjected to immunoprecipitation using NDR1 antibody or IgG immunoglobulins, as a negative control, followed by immunoblotting with the SnoN or NDR1 antibody. Cell lysates were also subjected to immunoblotting with the SnoN, NDR1 or actin antibody with the latter serving as a loading control. **** in A and B indicates significant difference from the control ($p < 0.0001$, t-test).

(TIF)

Figure S2 Related to Figure 2. A. Lysates of 293T cells expressing HA-NDR1 in the presence of the control RNAi vector, or NDR1 RNAi NDR1i-1 or NDR1i-2 plasmid were subjected to immunoblotting using the HA or actin antibody, with the latter to serve as a loading control. NDR1i-1 or NDR1i-2 induced 80 to 90 percent knockdown of NDR1. **B.** Lysates of NMuMG cells transfected with increasing concentrations of a plasmid expressing HA-NDR1 together with the TGF β -responsive 3TP-luciferase reporter and a transfection efficiency vector as described in Figure 2C, were subjected to immunoblotting using the HA or actin antibody. Images in A and B are representative blots from experiments that were repeated at least two independent times.

(TIF)

Figure S3 Related to Figure 4. A. Population growth of NMuMG cells expressing wild type (WT) or kinase-inactive (KR) NDR1, or control vector (–) after culturing for one, two, or three days in the absence or presence of 100 pM TGF β was determined by subjecting DNA dye (Hoechst)-labeled NMuMG cells to fluorescence microscopy and data analysis using the Cellomics KSR platform and Target Activation algorithm. Percent decrease in population growth of NMuMG cells by TGF β was quantified as described in Figure 4B. Data are presented as the mean \pm SEM of percent reduction of population growth of NMuMG cells by TGF β from three (day 1 and day 3) or five (day 2) independent experiments. ** or *** indicates significant difference from the respective control within each day at $p < 0.01$, or $P < 0.001$, respectively (ANOVA). **B.** Representative fluorescence images of NMuMG cells one day post transfection with control RNAi, NDR1i or NDRi plasmids as described Figure 4E, where the DNA dye Hoechst (blue) and GFP (green)-induced signals indicate total NMuMG cells and transfected NMuMG cells, respectively. Analysis of the GFP-labeled cells as compared to total cells using the target activation algorithm indicated approximately 50 percent transfection efficiency for all three sets of transfections. The width

of each micrograph corresponds to 330 μ m. **C.** For each experiment including the one shown in Figure 4E, triplicate average of GFP-positive cells at each TGF β concentration was determined. Data are presented as the mean \pm SEM of relative GFP-positive cell numbers from six (control and NDR1) or five (NDR1i) independent experiments. (TIF)

Figure S4 Related to Figure 5. Representative images of untreated or TGF β -treated NMuMG cells expressing wild type or kinase-inactive NDR1 or vector control that were subjected to indirect immunofluorescence using the Smad2 antibody and a Cy3-secondary antibody (red) and labeling with the DNA Hoechst dye (blue), and scanned by fluorescence microscopy. The width of each micrograph corresponds to 330 μ m. (TIF)

Figure S5 Related to Figure 6. A. Lysates of 293T cells coexpressing FLAG-NDR1 and HA-ubiquitin alone or together with the constitutively active TGF β type I receptor, harboring a mutation in Threonine 204 to aspartate, were subjected to immunoprecipitation using the FLAG antibody followed by immunoblotting with the HA or NDR1 antibody as described in Figure 6H. Ubiquitin-conjugated NDR1 protein species as indicated in and including the protein species in Figure 6H immunoblots were quantified and normalized to NDR1 levels in the immunoprecipitates. Data are presented as the mean \pm SEM (n = 3) of ubiquitin-conjugated NDR1 species relative to the ubiquitinated NDR1 in cells coexpressing NDR1 and ubiquitin. Significant difference between the two groups was determined using unpaired, two-tailed t-test. B. Lysates of untreated or MG132-treated 293T cells expressing FLAG-NDR1 alone or together with constitutively active receptor were subjected to FLAG and actin immunoblotting as described in Figure 6I. NDR1 protein species as indicated and including the protein species in Figure 6I were quantified and normalized to respective actin. Data are presented as the mean \pm SEM (n = 6) of NDR1 relative to NDR1 in cells expressing NDR1 alone and left in the absence of MG132. *** indicates significant difference from the control (p < 0.001, ANOVA). (TIF)

References

- Massague J (1990) The transforming growth factor-beta family. *Annu Rev Cell Biol* 6: 597–641.
- Roberts AB, Sporn MB (1990) The transforming growth factor-betas. In: Sporn MB, Roberts AB, editors. *Peptide growth factors and their receptors*. Heidelberg: Springer-Verlag, 419–472.
- Sporn MB, Roberts AB (1990) TGF-beta: problems and prospects. *Cell Regul* 12: 875–882.
- Wu MY, Hill CS (2009) Tgf-beta superfamily signaling in embryonic development and homeostasis. *Dev Cell* 16: 329–343.
- Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. *N Engl J Med* 342: 1350–1358.
- Lan HY (2011) Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. *Int J Biol Sci* 7: 1056–1067.
- Schmierer B, Hill CS (2007) TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. *Nat Rev Mol Cell Biol* 8: 970–982.
- Tatler AL, Jenkins G (2012) TGF-beta Activation and Lung Fibrosis. *Proc Am Thorac Soc* 9: 130–136.
- Iwano M (2010) EMT and TGF-beta in renal fibrosis. *Front Biosci (Schol Ed)* 2: 229–238.
- Gallagher AJ, Neil JR, Schiemann WP (2006) Role of transforming growth factor-beta in cancer progression. *Future Oncol* 2: 743–763.
- Kim SJ, Letterio J (2003) Transforming growth factor-beta signaling in normal and malignant hematopoiesis. *Leukemia* 17: 1731–1737.
- Massague J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. *Cell* 103: 295–309.
- Rahimi RA, Leof EB (2007) TGF-beta signaling: a tale of two responses. *J Cell Biochem* 102: 593–608.
- Meulmeester E, Ten Dijke P (2010) The dynamic roles of TGF-beta in cancer. *J Pathol* 223: 205–218.
- Attisano L, Wrana JL, Lopez-Casillas F, Massague J (1994) TGF-beta receptors and actions. *Biochim Biophys Acta* 1222: 71–80.
- Huang T, David L, Mendoza V, Yang Y, Villarreal M, et al. (2011) TGF-beta signalling is mediated by two autonomously functioning TbetaRI:TbetaRII pairs. *EMBO J* 30: 1263–1276.
- Massague J, Attisano L, Wrana JL (1994) The TGF-beta family and its composite receptors. *Trends Cell Biol* 4: 172–178.
- Wrana JL, Carcamo J, Attisano L, Cheifetz S, Zentella A, et al. (1992) The type II TGF-beta Receptor Signals Diverse Responses in Co-Operation with the Type I Receptor. *Cold Spring Harbour Symposia on Quantitative Biology*, 81–86.
- Wrana JL, Tran H, Attisano L, Arora K, Childs SR, et al. (1994) Two distinct transmembrane serine/threonine kinases from Drosophila form an activin receptor complex. *Mol Cell Biol* 14: 944–950.
- Miyazono K, Suzuki H, Imamura T (2003) Regulation of TGF-beta signaling and its roles in progression of tumors. *Cancer Sci* 94: 230–234.
- Wieser R, Wrana JL, Massague J (1995) GS domain mutations that constitutively activate TBR-I, the downstream signalling component in the TGF-beta receptor complex. *EMBO J* 14: 2199–2208.
- Wrana JL, Attisano L, Wieser R, Ventura F, Massague J (1994) Mechanism of activation of the TGF-beta receptor. *Nature* 370: 341–347.
- Massague J, Wotton D (2000) Transcriptional control by the TGF-beta/Smad signaling system. *Embo J* 19: 1745–1754.
- Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell* 113: 685–700.
- Abdollah S, Macias-Silva M, Tsukazaki T, Hayashi H, Attisano L, et al. (1997) TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for

Figure S6 NDR1 knockdown restores the ability of TGF β to inhibit cell proliferation in the breast MDA-MB-231 carcinoma cells. A. Lysates of MDA-MB-231 transfected with a control or NDR1 RNAi plasmids, were subjected to immunoblotting with an NDR1 or actin antibody. Values shown below lanes 1 and 2 represent actin-normalized NDR1 level expressed relative to the actin-normalized NDR1 level in the RNAi control vector transfected cells. B. GFP-expressing and DNA-Hoechst-labeled MDA-MB-231 cells transfected as in A and incubated one day post transfection with 0, 25, 100, or 400 pM TGF β for 72 h were imaged and quantified by fluorescence microscopy and the target activation bio-application, respectively, using the Cellomics KSR as in Figure 4 and Figure S3. Untreated or TGF β -treated cells were seeded in triplicates or quadruplicates in a 96-well plate, and population growth of GFP-positive cells were averaged. Data are presented as the mean \pm SEM of average population growth of GFP-positive MDA-MB-231 cells from five independent experiments expressed relative to the untreated control. C. MDA-MB-231 cells transfected as in A and left untreated or treated with 400 pM TGF β were incubated for the last hour with bromodeoxyuridine, and subjected to immunocytochemistry using a BrdU antibody, fluorescence microscopy and analysis as described in Figure 4. Target activation bioapplication was used to quantify ratio of GFP-expressing BrdU labeled cells, and averages of replicates quantified as in B. Data are presented as the mean \pm SEM of GFP-expressing BrdU-positive cells from 5 independent experiments. ** or *** indicates significant difference from the control at p < 0.01, or p < 0.001, respectively (ANOVA). (TIF)

Acknowledgments

We thank J. Wrana and F. Jirik for reagents.

Author Contributions

Conceived and designed the experiments: IP SP AB SB. Performed the experiments: IP SP LD AC CZ. Analyzed the data: IP SP SB AC CZ. Wrote the paper: IP SP AB SB.

- Smad2-Smad4 complex formation and signaling. *J Biol Chem* 272: 27678–27685.
26. Souchevnytskyi S, Tamaki K, Engstrom U, Wernstedt C, ten Dijke P, et al. (1997) Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. *J Biol Chem* 272: 28107–28115.
 27. Lagna G, Hata A, Hemmati-Brivanlou A, Massagué J (1996) Partnership between DPC4 and SMAD proteins in TGF- signalling pathways. *Nature* 383: 832–836.
 28. Lonn P, Moren A, Raja E, Dahl M, Moustakas A (2009) Regulating the stability of TGFbeta receptors and Smads. *Cell Res* 19: 21–35.
 29. Feng XH, Derynck R (2005) Specificity and Versatility in TGF- Signaling Through Smads. *Annu Rev Cell Dev Biol*.
 30. Wotton D, Massagué J (2001) Smad transcriptional corepressors in TGF beta family signaling. *Curr Top Microbiol Immunol* 254: 145–164.
 31. Wrana JL, Attisano L (2000) The Smad pathway. *Cyto Growth Factor Rev* in press.
 32. Luo K (2004) Ski and SnoN: negative regulators of TGF-beta signaling. *Curr Opin Genet Dev* 14: 65–70.
 33. Pot I, Bonni S (2008) SnoN in TGF-beta signaling and cancer biology. *Curr Mol Med* 8: 319–328.
 34. Pot I, Ikeuchi Y, Bonni A, Bonni S (2010) SnoN: bridging neurobiology and cancer biology. *Curr Mol Med* 10: 667–673.
 35. Bonni S, Bonni A (2012) SnoN signaling in proliferating cells and postmitotic neurons. *FEBS Lett* 586: 1977–1983.
 36. Deheuninck J, Luo K (2009) Ski and SnoN, potent negative regulators of TGF-beta signaling. *Cell Res* 19: 47–57.
 37. Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K (1999) Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. *Science* 286: 771–774.
 38. Sun Y, Liu X, Ng-Eaton E, Lodish HF, Weinberg RA (1999) SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor beta signaling. *Proc Natl Acad Sci U S A* 96: 12442–12447.
 39. Sarker KP, Kataoka H, Chan A, Netherton SJ, Pot I, et al. (2008) ING2 as a novel mediator of transforming growth factor-beta-dependent responses in epithelial cells. *J Biol Chem* 283: 13269–13279.
 40. Sarker KP, Wilson SM, Bonni S (2005) SnoN is a cell type-specific mediator of transforming growth factor-beta responses. *J Biol Chem* 280: 13037–13046.
 41. Hergovich A, Stegert MR, Schmitz D, Hemmings BA (2006) NDR kinases regulate essential cell processes from yeast to humans. *Nat Rev Mol Cell Biol* 7: 253–264.
 42. Cornils H, Kohler RS, Hergovich A, Hemmings BA (2011) Downstream of human NDR kinases: impacting on c-myc and p21 protein stability to control cell cycle progression. *Cell Cycle* 10: 1897–1904.
 43. Cornils H, Kohler RS, Hergovich A, Hemmings BA (2011) Human NDR kinases control G(1)/S cell cycle transition by directly regulating p21 stability. *Mol Cell Biol* 31: 1382–1395.
 44. Cornils H, Stegert MR, Hergovich A, Hynx D, Schmitz D, et al. (2010) Ablation of the kinase NDR1 predisposes mice to the development of T cell lymphoma. *Sci Signal* 3: ra47.
 45. Vichalkovski A, Gresko E, Cornils H, Hergovich A, Schmitz D, et al. (2008) NDR kinase is activated by RASSF1A/MST1 in response to Fas receptor stimulation and promotes apoptosis. *Curr Biol* 18: 1889–1895.
 46. Ultanir SK, Hertz NT, Li G, Ge WP, Burlingame AL, et al. (2012) Chemical genetic identification of NDR1/2 kinase substrates AAK1 and Rabin8 Uncovers their roles in dendrite arborization and spine development. *Neuron* 73: 1127–1142.
 47. Adeyinka A, Emberley E, Niu Y, Snell L, Murphy LC, et al. (2002) Analysis of gene expression in ductal carcinoma in situ of the breast. *Clin Cancer Res* 8: 3788–3795.
 48. Hergovich A, Cornils H, Hemmings BA (2008) Mammalian NDR protein kinases: from regulation to a role in centrosome duplication. *Biochim Biophys Acta* 1784: 3–15.
 49. Bonni S, Wang HR, Causing CG, Kavsak P, Stroschein SL, et al. (2001) TGF-beta induces assembly of a Smad2-Smur2 ubiquitin ligase complex that targets SnoN for degradation. *Nat Cell Biol* 3: 587–595.
 50. Stroschein SL, Bonni S, Wrana JL, Luo K (2001) Smad3 recruits the anaphase-promoting complex for ubiquitination and degradation of SnoN. *Genes Dev* 15: 2822–2836.
 51. Nakatani Y, Ogryzko V (2003) Immunoaffinity purification of mammalian protein complexes. *Methods Enzymol* 370: 430–444.
 52. Puig O, Caspary F, Rigaut G, Rutz B, Bouvet E, et al. (2001) The tandem affinity purification (TAP) method: a general procedure of protein complex purification. *Methods* 24: 218–229.
 53. Barrios-Rodiles M, Brown KR, Ozdamar B, Bose R, Liu Z, et al. (2005) High-throughput mapping of a dynamic signaling network in mammalian cells. *Science* 307: 1621–1625.
 54. Kortlever RM, Nijwening JH, Bernards R (2008) Transforming growth factor-beta requires its target plasminogen activator inhibitor-1 for cyostatic activity. *J Biol Chem* 283: 24308–24313.
 55. Wilkins-Port CE, Ye Q, Mazurkiewicz JE, Higgins PJ (2009) TGF-beta1+ EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for PAI-1. *Cancer Res* 69: 4081–4091.
 56. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, et al. (1992) TGF beta signals through a heteromeric protein kinase receptor complex. *Cell* 71: 1003–1014.
 57. Miettinen PJ, Ebner R, Lopez AR, Derynck R (1994) TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. *J Cell Biol* 127: 2021–2036.
 58. Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, et al. (2010) The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. *Dev Cell* 19: 831–844.
 59. Levy L, Howell M, Das D, Harkin S, Episkopou V, et al. (2007) Arkadia activates Smad3/Smad4-dependent transcription by triggering signal-induced SnoN degradation. *Mol Cell Biol* 27: 6068–6083.
 60. Nagano Y, Mavrakis KJ, Lee KL, Fujii T, Koinuma D, et al. (2007) Arkadia induces degradation of SnoN and c-Ski to enhance transforming growth factor-beta signaling. *J Biol Chem* 282: 20492–20501.
 61. Wan Y, Liu X, Kirschner MW (2001) The anaphase-promoting complex mediates TGF-beta signaling by targeting SnoN for destruction. *Mol Cell* 8: 1027–1039.
 62. Stegmuller J, Huynh MA, Yuan Z, Konishi Y, Bonni A (2008) TGFbeta-Smad2 signaling regulates the Cdh1-APC/SnoN pathway of axonal morphogenesis. *J Neurosci* 28: 1961–1969.
 63. Netherton SJ, Bonni S (2010) Suppression of TGFbeta-induced epithelial-mesenchymal transition like phenotype by a PIAS1 regulated sumoylation pathway in NMuMG epithelial cells. *PLoS One* 5: e13971.
 64. von Both I, Silvestri C, Erdemir T, Lickert H, Walls JR, et al. (2004) Foxh1 is essential for development of the anterior heart field. *Dev Cell* 7: 331–345.
 65. Huynh MA, Ikeuchi Y, Netherton S, de la Torre-Ubieda L, Kanadia R, et al. (2011) An isoform-specific SnoN1-FOXO1 repressor complex controls neuronal morphogenesis and positioning in the mammalian brain. *Neuron* 69: 930–944.
 66. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, et al. (1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. *J Cell Biol* 106: 761–771.
 67. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, et al. (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. *Mol Cell Biol* 7: 379–387.
 68. Heiz M, Grunberg J, Schubiger PA, Novak-Hofer I (2004) Hepatocyte growth factor-induced ectodomain shedding of cell adhesion molecule L1: role of the L1 cytoplasmic domain. *J Biol Chem* 279: 31149–31156.
 69. Owens RB (1974) Glandular epithelial cells from mice: a method for selective cultivation. *J Natl Cancer Inst* 52: 1375–1378.
 70. Owens RB, Smith HS, Hackett AJ (1974) Epithelial cell cultures from normal glandular tissue of mice. *J Natl Cancer Inst* 53: 261–269.
 71. Yingling JM, Das P, Savage C, Zhang M, Padgett RW, et al. (1996) Mammalian dwarfins are phosphorylated in response to transforming growth factor beta and are implicated in control of cell growth. *Proc Natl Acad Sci U S A* 93: 8940–8944.
 72. Hsu YH, Sarker KP, Pot I, Chan A, Netherton SJ, et al. (2006) Sumoylated SnoN represses transcription in a promoter-specific manner. *J Biol Chem* 281: 33008–33018.
 73. Bondareva A, Downey CM, Ayres F, Liu W, Boyd SK, et al. (2009) The lysyl oxidase inhibitor, beta-aminopropionitrile, diminishes the metastatic colonization potential of circulating breast cancer cells. *PLoS One* 4: e5620.
 74. Cailleau R, Young R, Olive M, Reeves WJ, Jr. (1974) Breast tumor cell lines from pleural effusions. *J Natl Cancer Inst* 53: 661–674.
 75. Eapen SA, Netherton SJ, Sarker KP, Deng L, Chan A, et al. (2012) Identification of a Novel Function for the Chromatin Remodeling Protein ING2 in Muscle Differentiation. *PLoS One* 7: e40684.
 76. Scherr M, Morgan MA, Eder M (2003) Gene silencing mediated by small interfering RNAs in mammalian cells. *Curr Med Chem* 10: 245–256.